Maxion Therapeutics

Maxion® Therapeutics | Home

Cambridge, United Kingdom · Founded 2020 · $88.0M raised

Headquarters
Cambridge
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$88.0M
Last Round
$72.0M Series AMar 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Maxion Therapeutics uses its patented KnotBody technology to create first-in-class and best-in-class protein therapeutics targeting ion channels and GPCRs. By fusing naturally occurring cysteine-rich miniproteins, or Knottins, into antibody binding loops, the platform combines millions of years of Knottin evolution with antibody engineering to address key challenges in ion channel and GPCR drug discovery. The company is leveraging this technology to deliver safe, efficacious, and long-acting drugs against previously undruggable targets.

Summary

Maxion Therapeutics is a Life Sciences company based in Cambridge, United Kingdom, founded in 2020. It has raised $88.0M in total across 2 rounds, most recently a $72.0M Series A round in Mar 2025. Investors include LifeArc, Monograph Capital and BGF.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2025
$72.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Maxion Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/maxion-therapeutics"><img src="https://indexed.vc/api/badge/company/maxion-therapeutics" alt="Maxion Therapeutics on Indexed.vc" width="260" height="76" /></a>